Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 3/20 | 0.56 |
| ▸ | HTR1B | P28222 | 2/20 | 0.56 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28356850 | 0.80 | SMN1; SMN2 (0.48) | HRH1HTR2ATAAR1 | |
| SCHEMBL5786004 | 0.75 | ALDH1A1 (0.37) | HRH1 | |
| SCHEMBL30784997 | 0.73 | HTR2A (0.44) | HTR2ATAAR1 | |
| SCHEMBL22783595 | 0.73 | HRH4 (0.38) | HRH1MTOR | |
| SCHEMBL29489942 | 0.72 | HTR1B (1.00) | HRH1HTR1BMTOR | |
| Hydrochloric Acid SCHEMBL8992515 | 0.70 | HRH4 (0.36) | HRH1MTOR | |
| SCHEMBL4720914 | 0.70 | HRH4 (0.35) | HRH1HTR1BMTORTAAR1 | |
| SCHEMBL11448189 | 0.70 | HRH2 (0.35) | HRH1 | |
| SCHEMBL1436268 | 0.69 | LOXL2 (0.40) | HRH1HTR1BHTR2AMTORTAAR1 | |
| SCHEMBL28861085 | 0.69 | HRH3 (0.38) | HRH1HTR1BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673146-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | Biohaven Therapeutics Ltd. (VG) | 2026-01-07 | — | — | EP | claimed |
| WO-2024182465-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | ALCO THERAPEUTICS, LLC (US) | 2024-09-06 | — | — | WO | claimed |
| US-20100204205-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE AGENT BY USING THEM IN COMBINATION | OBECURE LTD. (IL) | 2010-08-12 | — | — | US | claimed |
| US-20100160294-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCES, INC. | 2010-06-24 | — | — | US | claimed |
| EP-2167096-A1 | IMPROVING THE TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | Cypress Bioscience, Inc. (US) | 2010-03-31 | — | — | EP | claimed |
| US-20090275562-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCES, INC. (US) | 2009-11-05 | — | — | US | claimed |
| US-20090156581-A1 | Aminergic pharmaceutical compositions and methods | BOARD OF TRUSTREES OF MICHIGAN STATE UNIVERSITY (US) | 2009-06-18 | — | — | US | claimed |
| WO-2008157094-A1 | IMPROVING THE TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCE, INC. (US) | 2008-12-24 | — | — | WO | claimed |
| EP-4673146-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | Biohaven Therapeutics Ltd. (VG) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024182465-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | ALCO THERAPEUTICS, LLC (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20100204205-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE AGENT BY USING THEM IN COMBINATION | OBECURE LTD. (IL) | 2010-08-12 | — | — | US | disclosed |
| US-20100160294-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCES, INC. | 2010-06-24 | — | — | US | disclosed |
| EP-2167096-A1 | IMPROVING THE TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | Cypress Bioscience, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090275562-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCES, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090156581-A1 | Aminergic pharmaceutical compositions and methods | BOARD OF TRUSTREES OF MICHIGAN STATE UNIVERSITY (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2008157094-A1 | IMPROVING THE TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCE, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| EP-1885708-A2 | GPCR MODULATORS | Board of Trustees of Michigan State University (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006113557-A2 | GPCR MODULATORS | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275562-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | HTR2A, HTR2C, HTR3A | HRH1 39/4885HTR1B 7/4885HTR2A 1/4885 |
| US-20100160294-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | HTR2A, HTR3A, HTR2C | HRH1 29/4885HTR1B 9/4885HTR2A 1/4885 |
| US-20100204205-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE AGENT BY USING THEM IN COMBINATION | HTR2A, HTR3A, HTR2C | HRH1 16/4885HTR1B 8/4885HTR2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.